But phase III SANDPIPER trial showed the addition of taselisib to fulvestrant for oestrogen receptor‐positive, HER2‐negative, PI3KCA‐mutant, advanced breast cancer was not suggested given its toxicities and modest clinical benefit.358. The gene discussed is ERBB2; the disease is breast cancer.